ReviewTrends in cancer2019
Serrated Colorectal Cancer: The Road Less Travelled?
Review in Trends in cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Integrative Transcriptomic and Proteomic Profiling Identifies S100P as a Potential Functional Biomarker for Sessile Serrated Lesions.Digestive diseases and sciences · 2026Article
- Semaphorin 6D drives anti-tumor type I interferon responses to reprogram the tumor microenvironment in colorectal cancer.Cell death & disease · 2026Article
- Article
- Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer.Nature communications · 2025Article
- Clinical and immunopathological evaluation and its comparison with IHC consensus molecular subtypes of colorectal cancer.Scientific reports · 2025Article
- Construction and validation of machine learning-based predictive model for colorectal polyp recurrence one year after endoscopic mucosal resection.World journal of gastroenterology · 2025Article
- Article
- Associations of serum and tissue TIMP1 with host response and survival in colorectal cancer.Scientific reports · 2025Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Epithelial aPKC deficiency leads to stem cell loss preceding metaplasia in colorectal cancer initiation.Developmental cell · 2024Article
- Prevalence and predictive factors of colorectal sessile serrated lesions in younger individuals.Endoscopy · 2024Article
- Exploring the potential biological function of GRK2 in colorectal cancer.Functional & integrative genomics · 2024Article
- Clinicopathologic and endoscopic features of sessile serrated lesions and conventional adenomas: a large inpatient population-based study in China.Frontiers in oncology · 2024Article
- Increased circulating regulatory T cells and decreased follicular T helper cells are associated with colorectal carcinogenesis.Frontiers in immunology · 2024Article
- Enhanced SREBP2-driven cholesterol biosynthesis by PKCλ/ι deficiency in intestinal epithelial cells promotes aggressive serrated tumorigenesis.Nature communications · 2023Article
- Sessile serrated lesions with dysplasia: is it possible to nip them in the bud?Journal of gastroenterology · 2023Review
- Review
- Node-negative colon cancer: histological, molecular, and stromal features predicting disease recurrence.Molecular medicine (Cambridge, Mass.) · 2023Article
- Nanomedicines: intervention in inflammatory pathways of cancer.Inflammopharmacology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Studies of colorectal cancer (CRC) originating through the conventional adenoma-carcinoma sequence have provided insight into the molecular mechanisms controlling its initiation and progression. Less is known about the alternative 'serrated' pathway, which has been associated with BRAF mutation and microsatellite instability. Recent transcriptomics approaches to classify human CRC revealed that mesenchymal and/or desmoplastic features combined with an immunosuppressive microenvironment are key determinants of CRC with the poorest prognosis. Importantly, these aggressive CRCs harbor the characteristics of serrated tumors, suggesting that initiation through this alternative pathway determines how aggressive the CRC becomes. Here, we review recent evidence on how serrated carcinogenesis contributes to the subtype of CRC with the poorest prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.